Patents Assigned to BIO MODELING SYSTEMS OU BMSYSTEMS
  • Use of anti-connexin agents for modulating the therapeutic effect of psychotropic drugs
    Patent number: 11077080
    Abstract: The invention first relates to a product containing at least one connexin-blocking agent and a psychotropic drug as combination products for use simultaneously, separately, or spread over time in patients suffering from psychiatric and/or neurodegenerative disorders. The connexin-blocking agent is advantageously selected from the group comprising meclofenamic acid, 18-?-glycyrrhetinic acid, carbenoxolone, mefloquine, and 2-APB, and preferably consists of meclofenamic acid. The invention first relates to a product containing at least one connexin-blocking agent and a psychotropic drug as combination products for use simultaneously, separately, or spread over time in patients suffering from psychiatric and/or neurodegenerative disorders. The connexin-blocking agent is advantageously selected from the group comprising meclofenamic acid, 18-?-glycyrrhetinic acid, carbenoxolone, mefloquine, and 2-APB, and preferably consists of meclofenamic acid.
    Type: Grant
    Filed: June 10, 2015
    Date of Patent: August 3, 2021
    Assignees: COMMISSARIAT A L'ENERGIE ATOMIQUE AUX ENERGIES ALTERNATIVES, BIO MODELING SYSTEMS OU BMSYSTEMS
    Inventors: Franck Mouthon, Mathieu Charveriat, Jean-Philippe Deslys, François Iris
  • USE OF ANTI-CONNEXIN AGENTS FOR MODULATING THE THERAPEUTIC EFFECT OF PSYCHOTROPIC DRUGS
    Publication number: 20110172188
    Abstract: The invention first relates to a product containing at least one connexin-blocking agent and a psychotropic drug as combination products for use simultaneously, separately, or spread over time in patients suffering from psychiatric and/or neurodegenerative disorders. The connexin-blocking agent is advantageously selected from the group comprising meclofenamic acid, 18-?-glycyrrhetinic acid, carbenoxolone, mefloquine, and 2-APB, and preferably consists of meclofenamic acid. The invention first relates to a product containing at least one connexin-blocking agent and a psychotropic drug as combination products for use simultaneously, separately, or spread over time in patients suffering from psychiatric and/or neurodegenerative disorders. The connexin-blocking agent is advantageously selected from the group comprising meclofenamic acid, 18-?-glycyrrhetinic acid, carbenoxolone, mefloquine, and 2-APB, and preferably consists of meclofenamic acid.
    Type: Application
    Filed: September 10, 2009
    Publication date: July 14, 2011
    Applicant: BIO MODELING SYSTEMS OU BMSYSTEMS
    Inventors: Franck Mouthon, Mathieu Charveriat, Jean-Philippe Deslys, Francois Iris